AbbVie’s Humira strategy to be scrutinised in first evergreening unclean hands challenge
In a Delaware case Boehringer Ingelheim accuses the Illinois company of improper conduct in deliberately constructing a patent thicket to protect against generic versions of its blockbuster drug.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.